ストックスクリーナーアプリを入手
433.07
4.56%
-20.67
プレマーケット:
434.02
0.95
+0.22%
前日終値:
$453.74
開ける：
$450.95
24時間の取引高:
1.92M
Relative Volume:
1.36
時価総額：
$110.01B
収益：
$12.07B
当期純損益:
$3.95B
株価収益率:
28.24
EPS:
15.3349
ネットキャッシュフロー:
$3.19B
1週間 パフォーマンス:
-4.61%
1か月 パフォーマンス:
-12.83%
6か月 パフォーマンス:
+12.27%
1年 パフォーマンス:
-13.83%
1日の値動き範囲:
$431.01
$452.00
1週間の範囲:
$431.01
$463.78
52週間の値動き範囲:
$362.50
$510.77
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | アップグレード | Maxim Group | Hold → Buy |
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-03-10 | 繰り返されました | Oppenheimer | Outperform |
| 2026-02-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Best Biotech Stocks To Watch TodayMarch 29th - MarketBeat
Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta - TechStock²
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment - ChartMill
Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 - Insider Monkey
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vanguard (VRTX) parent reports 0 shares; subsidiaries to report holdings separately - Stock Titan
Vertex Pharmaceuticals Tumbles Over 3.4% – What’s Behind the Sudden Drop? - Bitget
Carmen Bozic files Form 144; VRTX (NASDAQ: VRTX) insider sales listed - Stock Titan
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Merck & Company (MRK) and Abbott Laboratories (ABT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Congress Asset Management Co. - MarketBeat
Baker Chad R Sells 8,990 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Positive phase 3 IgA nephropathy data sees Vertex Pharmaceuticals stock slip despite promising update - Traders Union
Vertex Pharmaceuticals (NASDAQ:VRTX) Raised to "Strong-Buy" at Truist Financial - MarketBeat
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Vertex Pharmaceuticals (VRTX) Outperforms the Market: Find Out the Reasons - Bitget
Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here's Why - Yahoo Finance
Top 1% Biotech Crashes Despite 'Overwhelmingly Positive' Data - Investor's Business Daily
Where Will Vertex Pharmaceuticals Be in 1 Year? - AOL.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Where Will Vertex Pharmaceuticals Be in 1 Year? - The Motley Fool
Maze set to target Vertex as kidney disease drug succeeds in Phase II trial - Yahoo Finance
Vertex Pharmaceuticals Incorporated : 2025 (2025 Political Engagement Principles) - marketscreener.com
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex - Endpoints News
DAVENPORT & Co LLC Trims Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now? - Insider Monkey
Assenagon Asset Management S.A. Has $377.58 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - Defense World
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Truist raises Vertex (VRTX) price target following Phase 3 trial results - MSN
Wealth Enhancement Advisory Services LLC Buys 7,777 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results - Insider Monkey
Westview Management dba Westview Investment Advisors Invests $2.85 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Gradient Investments LLC Has $19.76 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Nordea Investment Management AB Has $202.61 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Tokenized Stock (Ondo) price today, VRTXon to USD live price, marketcap and chart - CoinMarketCap
How Vertex’s IgA Nephropathy Data and Accelerated FDA Pathway At Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story - Yahoo Finance
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - AOL.com
Cooper Financial Group Increases Vertex Pharmaceuticals Stake - National Today
Cooper Financial Group Acquires 3,021 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Vertex Pharma stock faces pressure amid CF dominance and pipeline uncertainties in 2026 - AD HOC NEWS
Here’s what analysts are saying about Vertex Pharmaceuticals (VRTX) - MSN
Vertex Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VRTX - Benzinga
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 4 March - Investing.com
Oppenheimer upgrades Vertex Pharmaceuticals (VRTX) - MSN
Promising Biotech Stocks To Follow TodayMarch 20th - MarketBeat
VRTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vertex Pharma stock faces pressure amid CF growth and pipeline uncertainties - AD HOC NEWS
Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026 - FinancialContent
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
2.20%
大文字化:
|
ボリューム (24 時間):